Close Menu

NEW YORK – Invitae said this week that it completed its acquisition of Singular Bio on June 19. The deal was announced June 17. At closing, Invitae issued about 2.5 million shares of its common stock and approximately $5.7 million in cash to the former security holders of Singular Bio. Part of the cash consideration is being held back to satisfy potential indemnification obligations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.